ATE470725T1 - Warfarinsensibilität vorhersagende genetische varianten von vkorc1 - Google Patents

Warfarinsensibilität vorhersagende genetische varianten von vkorc1

Info

Publication number
ATE470725T1
ATE470725T1 AT05855433T AT05855433T ATE470725T1 AT E470725 T1 ATE470725 T1 AT E470725T1 AT 05855433 T AT05855433 T AT 05855433T AT 05855433 T AT05855433 T AT 05855433T AT E470725 T1 ATE470725 T1 AT E470725T1
Authority
AT
Austria
Prior art keywords
warfar
vkorc1
insensitivity
genetic variants
polymorphism
Prior art date
Application number
AT05855433T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Hsiang-Yu Yuan
Jin-Jer Chen
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE470725(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica filed Critical Academia Sinica
Application granted granted Critical
Publication of ATE470725T1 publication Critical patent/ATE470725T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05855433T 2004-12-21 2005-12-21 Warfarinsensibilität vorhersagende genetische varianten von vkorc1 ATE470725T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63883704P 2004-12-21 2004-12-21
US67969405P 2005-05-10 2005-05-10
PCT/US2005/046869 WO2006069339A2 (en) 2004-12-21 2005-12-21 Genetic variants of vkorci predicting warfarin sensitivity

Publications (1)

Publication Number Publication Date
ATE470725T1 true ATE470725T1 (de) 2010-06-15

Family

ID=36602356

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05855433T ATE470725T1 (de) 2004-12-21 2005-12-21 Warfarinsensibilität vorhersagende genetische varianten von vkorc1

Country Status (18)

Country Link
US (2) US20060166239A1 (de)
EP (2) EP1831402B1 (de)
JP (1) JP4516990B2 (de)
KR (1) KR101178463B1 (de)
CN (1) CN101142322B (de)
AT (1) ATE470725T1 (de)
AU (1) AU2005319028B2 (de)
BR (1) BRPI0519570A2 (de)
CA (1) CA2591840C (de)
DE (1) DE602005021821D1 (de)
DK (1) DK1831402T3 (de)
ES (1) ES2347167T3 (de)
MX (1) MX2007007568A (de)
NZ (1) NZ556461A (de)
PL (1) PL1831402T3 (de)
PT (1) PT1831402E (de)
TW (1) TWI334886B (de)
WO (1) WO2006069339A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
JP5348840B2 (ja) 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
DE602004025157D1 (de) * 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
US7445896B2 (en) 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
JP2009517186A (ja) * 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化
US8380539B2 (en) * 2006-05-09 2013-02-19 University Of Louisville Research Foundation, Inc. Personalized medicine management software
US8039212B2 (en) * 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
WO2010048020A1 (en) * 2008-10-20 2010-04-29 Epitome Pharmaceuticals Limited Methods and systems for improved pharmaceutical intervention in coagulation control
KR101157135B1 (ko) * 2008-12-29 2012-06-18 인제대학교 산학협력단 항응고제의 약물반응과 관련된 유전자의 변이 유전형 결정방법
US20100227776A1 (en) * 2009-03-05 2010-09-09 The Ohio State University Rapid Genotyping of SNPs
CN102268476B (zh) * 2010-06-01 2014-02-19 爱科来株式会社 Vkorc1基因的第-1639位碱基的多态性检测方法、以及用于该方法的核酸探针和试剂盒
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
US9290799B2 (en) * 2012-08-21 2016-03-22 Industrial Technology Research Institute System and method for detecting biological materials
CN103173443B (zh) * 2013-03-22 2016-08-24 卫生部北京医院 包括1300a>t突变的cyp2c9基因片段、所编码的蛋白质片段及其应用
CN110506128A (zh) 2016-12-09 2019-11-26 博德研究所 基于crispr效应系统的诊断
KR20190140918A (ko) 2017-03-15 2019-12-20 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 검출을 위한 crispr 이펙터 시스템 기반 진단
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
US10249389B2 (en) * 2017-05-12 2019-04-02 The Regents Of The University Of Michigan Individual and cohort pharmacological phenotype prediction platform
AU2019213047B2 (en) 2018-01-29 2025-07-24 Massachusetts Institute Of Technology CRISPR effector system based diagnostics
WO2020186223A1 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Sherlock assays for tick-borne diseases
CN110592206A (zh) * 2019-09-11 2019-12-20 上海交通大学 一种利用rs9934438检测华法药效的试剂盒
KR102506347B1 (ko) 2021-05-11 2023-03-03 충북대학교 산학협력단 와파린 치료에 따른 출혈 부작용 위험 예측용 다형성 마커 및 이를 이용한 와파린 치료에 따른 출혈 부작용 위험 예측 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492115B1 (en) * 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
DE602004025157D1 (de) * 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
WO2006044686A2 (en) * 2004-10-18 2006-04-27 University Of Washington Methods and compositions for predicting drug responses
US20080005732A1 (en) * 2006-05-11 2008-01-03 Coon Robert F Method and System for Integrating Software Update Services with Software Applications

Also Published As

Publication number Publication date
AU2005319028B2 (en) 2010-09-16
CA2591840C (en) 2012-07-10
TW200637918A (en) 2006-11-01
KR101178463B1 (ko) 2012-09-07
CN101142322A (zh) 2008-03-12
BRPI0519570A2 (pt) 2009-01-27
EP1831402B1 (de) 2010-06-09
AU2005319028A1 (en) 2006-06-29
DE602005021821D1 (de) 2010-07-22
HK1117571A1 (en) 2009-01-16
DK1831402T3 (da) 2010-09-20
WO2006069339A3 (en) 2006-10-12
TWI334886B (en) 2010-12-21
CA2591840A1 (en) 2006-06-29
PL1831402T3 (pl) 2010-12-31
WO2006069339A2 (en) 2006-06-29
ES2347167T3 (es) 2010-10-26
NZ556461A (en) 2009-12-24
JP4516990B2 (ja) 2010-08-04
WO2006069339A8 (en) 2010-06-03
CN101142322B (zh) 2011-09-21
KR20080005179A (ko) 2008-01-10
EP1831402A2 (de) 2007-09-12
US20060166239A1 (en) 2006-07-27
US20110236885A1 (en) 2011-09-29
JP2008523844A (ja) 2008-07-10
PT1831402E (pt) 2010-09-10
EP2246445A1 (de) 2010-11-03
MX2007007568A (es) 2008-03-11

Similar Documents

Publication Publication Date Title
ATE470725T1 (de) Warfarinsensibilität vorhersagende genetische varianten von vkorc1
DE602005013153D1 (de) Assoziation von SNPs in PPAR gamma mit Osteoporose
ATE408032T1 (de) Esr1 und gebärmutterhalskrebs
EP2064345A4 (de) Psorase-assoziierte genetische polymorphien, nachweisverfahren dafür und ihre verwendung
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
SG191078A1 (en) Improved method and kit for determining severity and progression of periodontal disease
ATE523601T1 (de) Verfahren und zusammensetzungen zur vorhersage der reaktion auf warfarin
ATE488772T1 (de) Biomarker zur beurteilung der leberfunktion
Hamadeh et al. Impact of GGCX, STX1B and FPGS polymorphisms on warfarin dose requirements in European‐Americans and Egyptians
ATE540966T1 (de) Von phenoxazinon abgeleitete neue enzymsubstrate und deren verwendung als entwickler bei der detektion von mikroorganismen mit peptidaseaktivität
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
DE602004005026D1 (de) RT-PCR-Verfahren zum quantitativen Nachweis von HDV
Lopez‐Rodriguez et al. Genetic Variants of Interferon‐Stimulated Genes and IL‐28B as Host Prognostic Factors of Response to Combination Treatment for Chronic Hepatitis C
WO2008018789A3 (en) Methods and means for diagnosing and treatment of osteoarthritis
RU2005103200A (ru) Способ прогнозирования развития сахарного диабета типа 1 в популяциях народов башкортостана
RU2011107170A (ru) Способ определения наследственной предрасположенности к развитию инфаркта миокарда у лиц без клинических проявлений ишемической болезни сердца
BRPI0418722A (pt) ensaios baseados em ácidos nucléicos para identificação de polimorfismos do receptor fc
ATE498021T1 (de) Verwendung genetischer polymorphismen zur vorhersage arzneistoffinduzierter hepatotoxizität
EP1829979A4 (de) Verfahren zur identifizierung eines gens mit variabler expression
DE602005006727D1 (de) Mit vorzeitiger canities in verbindung gebrachte polymorphismen von chromosom 9
ATE529532T1 (de) Genotyp spezifischer detektion von chlamydophila psittaci
WO2007014338A8 (en) Single nucleotide polymorphisms associated with susceptibility to cardiovascular disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1831402

Country of ref document: EP